000136944 001__ 136944
000136944 005__ 20240229105107.0
000136944 0247_ $$2pmid$$apmid:30125928
000136944 037__ $$aDKFZ-2018-01373
000136944 041__ $$aeng
000136944 082__ $$a610
000136944 1001_ $$aBulut, Olcay Cem$$b0
000136944 245__ $$aImpact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia.
000136944 260__ $$aStuttgart$$bSchattauer$$c2018
000136944 3367_ $$2DRIVER$$aarticle
000136944 3367_ $$2DataCite$$aOutput Types/Journal article
000136944 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536664638_12888
000136944 3367_ $$2BibTeX$$aARTICLE
000136944 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136944 3367_ $$00$$2EndNote$$aJournal Article
000136944 520__ $$aXerostomia following radioiodine therapy (RIT) in patients suffering from differentiated thyroid cancer is a common side effect in 2 % to 67 % of patients treated with radioiodine (I-131). In order to evaluate the impact of sialendoscopy on health related quality of life (HRQOL) in patients suffering from therapy induced sialadenitis and xerostomia, we analyzed findings from two dedicated questionnaires (Xerostomy Questionnaire XQ and Xerostomy Inventory XI) in patients before and three months after sialendoscopy.In total, 12 patients suffering from differentiated thyroid carcinoma (10 women and 2 men) were evaluated. All patients had experienced conservative management. Patients were offered a sialendoscopy procedure if no major contradictions were present. Patients who denied the procedure formed the control group. Pre- and (three months) postoperative HRQOL was measured with the Patient Reported Outcome Measures (PROM) Xerostomia Questionnaire (XQ) and the Xerostomia Inventory (XI), as well as by a pre- and post-interventional salivary gland scintigram. Patients were graded according to their sialendoscopical findings.Interventional group presented with significant improvements in HRQOL measurements regarding XQ and XI-scores three months postoperatively. Control group showed no significant changes in the XQ or the XI scores. Number of RIT and cumulative activity of I-131 did not correlate with higher disease grade in regards to sialendoscopical findings nor did it correlate with higher XQand XI scores. Pre- and post-interventional salivary gland scintigram stated that parotid glands are more severely damaged than submandibular glands (SMG), but no significant scintigraphically changes could be detected after sialendoscopy.Sialendoscopy in patients suffering from therapy induced sialadenitis and xerostomia seems to be beneficial when evaluating the impact on HRQOL. Functional parameters measured by salivary gland scintigram did not show significant changes in post-interventional scintigrams.
000136944 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136944 588__ $$aDataset connected to PubMed,
000136944 7001_ $$aHaufe, Sabine$$b1
000136944 7001_ $$aHohenberger, Ralph$$b2
000136944 7001_ $$aHein, Matti$$b3
000136944 7001_ $$aKratochwil, Clemens$$b4
000136944 7001_ $$aRathke, Hendrik$$b5
000136944 7001_ $$aPlinkert, Peter K$$b6
000136944 7001_ $$aBaumann, Ingo$$b7
000136944 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b8$$udkfz
000136944 7001_ $$aHaberkorn, Uwe$$b9
000136944 7001_ $$aFlechsig, Paul$$b10
000136944 773__ $$0PERI:(DE-600)2030804-8$$gVol. 57, no. 4$$n4$$p160-167$$tNuklearmedizin$$v57$$x0029-5566$$y2018
000136944 909CO $$ooai:inrepo02.dkfz.de:136944$$pVDB
000136944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136944 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136944 9141_ $$y2018
000136944 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUKLEARMED-NUCL MED : 2015
000136944 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136944 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136944 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136944 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136944 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136944 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136944 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136944 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136944 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000136944 980__ $$ajournal
000136944 980__ $$aVDB
000136944 980__ $$aI:(DE-He78)C060-20160331
000136944 980__ $$aUNRESTRICTED